Johnson & Johnson $JNJ Shares Sold by Verdence Capital Advisors LLC

Verdence Capital Advisors LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 12.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 38,126 shares of the company’s stock after selling 5,586 shares during the period. Verdence Capital Advisors LLC’s holdings in Johnson & Johnson were worth $7,255,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $27,000. Clayton Financial Group LLC acquired a new stake in Johnson & Johnson in the third quarter worth $28,000. Semmax Financial Advisors Inc. lifted its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the second quarter valued at $35,000. Finally, Signature Resources Capital Management LLC grew its position in shares of Johnson & Johnson by 262.9% during the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after acquiring an additional 184 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 revenue beat and 2026 guidance above consensus — management raised FY2026 sales and EPS targets, signaling mid?single?digit organic growth and margin improvement. Johnson & Johnson reports Q4 and Full-Year 2025 results
• Positive Sentiment: MedTech and oncology drove top?line strength (MedTech up mid?single digits; strong Darzalex and other cancer drug growth), supporting the company’s revenue trajectory beyond STELARA. Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth
• Positive Sentiment: Technicals and analyst sentiment remain constructive — MarketBeat highlights a trend?following buy signal and rising analyst price targets, which could limit downside and support future upside. Johnson & Johnson Quietly Triggers a Trend Following Buy Signal
• Neutral Sentiment: EPS outcome was mixed: adjusted EPS roughly in line (small beat vs. some consensus figures) and margins broadly as expected — solid but not overpowering enough to eliminate near?term concerns. Johnson & Johnson (JNJ) Tops Q4 Earnings and Revenue Estimates
• Negative Sentiment: Talc litigation advanced this week as plaintiffs cleared a key expert testimony hurdle — a reminder of legacy legal risk that can create episodic share pressure and potential liabilities. Johnson & Johnson Talc Plaintiffs Clear Key Expert Testimony Hurdle
• Negative Sentiment: STELARA sales plunged after loss of exclusivity and biosimilar competition (material YOY decline), which is a sizable headwind given STELARA’s previous revenue contribution. That dynamic is a key reason shares traded down despite the beat. J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales
• Negative Sentiment: Company flagged a hit from a recent drug?pricing deal with the administration (described as “hundreds of millions” of dollars), which tempers net profit upside and adds near?term uncertainty. Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Wall Street Analyst Weigh In

A number of research firms have issued reports on JNJ. Freedom Capital lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 16th. Wells Fargo & Company increased their price objective on Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Royal Bank Of Canada set a $240.00 price target on Johnson & Johnson in a research note on Wednesday, December 17th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $213.33.

Johnson & Johnson Stock Down 0.0%

JNJ opened at $218.12 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company has a market capitalization of $525.52 billion, a PE ratio of 21.05, a P/E/G ratio of 2.24 and a beta of 0.34. The stock’s fifty day moving average is $207.39 and its 200-day moving average is $188.27. Johnson & Johnson has a one year low of $141.50 and a one year high of $220.11.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.46. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.56 billion for the quarter, compared to analyst estimates of $24.14 billion. During the same period in the previous year, the company earned $2.04 earnings per share. Johnson & Johnson’s revenue was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.